Reuters
The panel voted 20-3 against a proposal from Merck and Johnson & Johnson for a nonprescription, low dose version of Mevacor, part of the statin family of drugs used to lower cholesterol and heart disease risk.
The Food and Drug Administration (news - web sites) usually follows the recommendations of the advisory panels.
More...
|